(IMNM) Immunome - Ratings and Ratios
Antibody, Oncology, Bispecific, Precision, Immunotherapy
IMNM EPS (Earnings per Share)
IMNM Revenue
Description: IMNM Immunome
Immunome Inc. (NASDAQ:IMNM) trades at roughly $9.95 per share, positioning it near the midpoint of its 52‑week range ($5.56‑$15.97). The stock’s 20‑day moving average ($10.07) sits above the 50‑day ($9.75) and 200‑day ($9.65) averages, indicating short‑term price pressure despite a longer‑term uptrend. An average true range of $0.47 translates to ~4.7 % daily volatility, while a beta of 1.93 signals amplified movements relative to the broader market.
Key performance indicators for a biotech at this stage include cash runway, R&D intensity, and pipeline milestones. Immunome reported cash and cash equivalents of approximately $120 million, sufficient for roughly 12‑18 months of operating expenses at its current burn rate of $7‑8 million per quarter. R&D expenditures constitute roughly 45 % of total operating costs, reflecting its focus on advancing multiple immunotherapy candidates through pre‑clinical and early‑clinical phases.
Revenue generation remains negligible, with the company still reliant on equity financing and strategic collaborations. Recent partnership agreements have provided non‑dilutive funding streams of $10‑15 million, contingent on achieving defined clinical endpoints. These milestones act as primary catalysts for share price appreciation, as each successful data readout reduces execution risk and can unlock additional capital.
Economic drivers influencing IMNM’s valuation include FDA regulatory timelines, the broader biotech funding environment, and macro‑level healthcare spending trends. A favorable regulatory outcome for any of its lead programs could compress the risk premium, while tightening capital markets or adverse policy shifts (e.g., drug pricing reforms) would pressure valuation multiples.
Liquidity metrics show an average daily volume of ~577 k shares, supporting moderate trade execution but still exposing the stock to price swings on relatively small order flow. Institutional ownership sits near 30 %, indicating a balanced mix of strategic investors and retail participation.
IMNM Stock Overview
| Market Cap in USD | 808m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2020-10-02 |
IMNM Stock Ratings
| Growth Rating | -2.92% |
| Fundamental | 29.2% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -50.8% |
| Analyst Rating | 4.78 of 5 |
IMNM Dividends
Currently no dividends paidIMNM Growth Ratios
| Growth Correlation 3m | 31.5% |
| Growth Correlation 12m | -58.6% |
| Growth Correlation 5y | -13.9% |
| CAGR 5y | 23.33% |
| CAGR/Max DD 3y | 0.29 |
| CAGR/Mean DD 3y | 0.76 |
| Sharpe Ratio 12m | -1.02 |
| Alpha | 0.09 |
| Beta | 0.804 |
| Volatility | 86.20% |
| Current Volume | 1162.4k |
| Average Volume 20d | 911k |
| Stop Loss | 8.3 (-7.7%) |
| Signal | -1.58 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-212.4m TTM) > 0 and > 6% of Revenue (6% = 755.3k TTM) |
| FCFTA -0.40 (>2.0%) and ΔFCFTA -36.98pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 2022 % (prev 2266 %; Δ -244.1pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.60 (>3.0%) and CFO -178.7m > Net Income -212.4m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 12.13 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (87.0m) change vs 12m ago 45.17% (target <= -2.0% for YES) |
| Gross Margin 79.25% (prev 87.40%; Δ -8.15pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 4.25% (prev 3.64%; Δ 0.61pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' -28.64
| (A) 0.86 = (Total Current Assets 277.4m - Total Current Liabilities 22.9m) / Total Assets 296.3m |
| (B) -2.03 = Retained Earnings (Balance) -600.8m / Total Assets 296.3m |
| warn (B) unusual magnitude: -2.03 — check mapping/units |
| (C) -0.64 = EBIT TTM -190.5m / Avg Total Assets 296.3m |
| (D) -22.24 = Book Value of Equity -600.8m / Total Liabilities 27.0m |
| Total Rating: -28.64 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 29.20
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -20.81% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.10 = 2.50 |
| 5. Debt/Ebitda -0.14 = -2.50 |
| 6. ROIC - WACC (= -87.08)% = -12.50 |
| 7. RoE -87.36% = -2.50 |
| 8. Rev. Trend 59.48% = 4.46 |
| 9. EPS Trend -5.07% = -0.25 |
What is the price of IMNM shares?
Over the past week, the price has changed by -0.11%, over one month by -12.29%, over three months by +0.45% and over the past year by -41.62%.
Is Immunome a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of IMNM is around 7.45 USD . This means that IMNM is currently overvalued and has a potential downside of -17.13%.
Is IMNM a buy, sell or hold?
- Strong Buy: 7
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the IMNM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 23.6 | 162.1% |
| Analysts Target Price | 23.6 | 162.1% |
| ValueRay Target Price | 8.3 | -7.5% |
Last update: 2025-09-04 04:40
IMNM Fundamental Data Overview
CCE Cash And Equivalents = 268.0m USD (Cash And Short Term Investments, last quarter)
P/S = 64.1654
P/B = 3.0742
Beta = 1.932
Revenue TTM = 12.6m USD
EBIT TTM = -190.5m USD
EBITDA TTM = -187.9m USD
Long Term Debt = 4.14m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 22.9m USD (from totalCurrentLiabilities, last quarter)
Debt = 27.0m USD (Calculated: Short Term 22.9m + Long Term 4.14m)
Net Debt = -139.7m USD (from netDebt column, last quarter)
Enterprise Value = 566.8m USD (807.8m + Debt 27.0m - CCE 268.0m)
Interest Coverage Ratio = unknown (Ebit TTM -190.5m / Interest Expense TTM 0.0)
FCF Yield = -20.81% (FCF TTM -118.0m / Enterprise Value 566.8m)
FCF Margin = -937.1% (FCF TTM -118.0m / Revenue TTM 12.6m)
Net Margin = -1687 % (Net Income TTM -212.4m / Revenue TTM 12.6m)
Gross Margin = 79.25% ((Revenue TTM 12.6m - Cost of Revenue TTM 2.61m) / Revenue TTM)
Tobins Q-Ratio = -0.94 (set to none) (Enterprise Value 566.8m / Book Value Of Equity -600.8m)
Interest Expense / Debt = 0.74% (Interest Expense 201.0k / Debt 27.0m)
Taxrate = 21.0% (US default)
NOPAT = -190.5m (EBIT -190.5m, no tax applied on loss)
Current Ratio = 12.13 (Total Current Assets 277.4m / Total Current Liabilities 22.9m)
Debt / Equity = 0.10 (Debt 27.0m / last Quarter total Stockholder Equity 269.3m)
Debt / EBITDA = -0.14 (Net Debt -139.7m / EBITDA -187.9m)
Debt / FCF = -0.23 (Debt 27.0m / FCF TTM -118.0m)
Total Stockholder Equity = 243.1m (last 4 quarters mean)
RoA = -71.68% (Net Income -212.4m, Total Assets 296.3m )
RoE = -87.36% (Net Income TTM -212.4m / Total Stockholder Equity 243.1m)
RoCE = -77.06% (Ebit -190.5m / (Equity 243.1m + L.T.Debt 4.14m))
RoIC = -78.37% (NOPAT -190.5m / Invested Capital 243.1m)
WACC = 8.71% (E(807.8m)/V(834.8m) * Re(8.98%)) + (D(27.0m)/V(834.8m) * Rd(0.74%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 81.82 | Cagr: 19.62%
Discount Rate = 8.98% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -118.0m)
EPS Correlation: -5.07 | EPS CAGR: 2.52% | SUE: 0.09 | # QB: 0
Revenue Correlation: 59.48 | Revenue CAGR: 169.1% | SUE: N/A | # QB: None
Additional Sources for IMNM Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle